Oxurion NV: Oxurion Announces Upcoming Pre-Clinical Data Presentation on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Leuven, BELGIUM, Boston, MA, US - 11 April 2022 - 7.00 AM CET - Oxurion NV(Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a

Related Keywords

Colorado ,United States ,Boston ,Massachusetts ,Leuven ,Region Flamande ,Belgium ,Denver ,Van Bergen ,Tom Graney ,Michael Dillen ,Sylvie Berrebi Frazer Hall ,Christopher Brinzey ,Company Annual ,Association For Research ,Euronext Brussels ,Annual Meeting ,Tine Van Bergen ,Senior Scientist ,Oxurion ,Nnounces ,Pcoming ,Linical ,Data ,Presentation ,Treatment ,Diabetic ,Macular ,Bedema ,022 ,Association ,Research ,Vision ,Ophthalmology ,Drvo ,Nnual ,Meeting ,